NuvOx is a Phase IIb platform biotech company. Focusing on reversing hypoxia (lack of oxygen), the root cause of many life-threatening diseases, NuvOx develops a first-in-class oxygen therapeutic that has the potential of $20bn+ ultimate revenue, applicable in oncology, neuro/CV, ARDS, and others. NuvOx has positive Phase Ib/IIa human data in brain cancer and stroke, pre-clinical data in immuno-oncology/ ARDS/other indications, and de-risked execution pathway to bring it to market. We have officially started recruiting patients for Phase IIb brain cancer trial and will be entering into Phase IIb stroke trial in UK this year. With incredible capital efficiency, the company strives to achieve 10x exit returns for investors in 2-3 years' time frame.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Our lead product is NanO2. Dodecafluoropentane is the active pharmaceutical ingredient of NanO2. As gas, it carries ∼ 1,000 x as much O2 as liquids, and is injected IV as emulsion of nanobubbles, active at 1/ 200th - 1/ 1000th dose of prior agents. NanO2 brings First-In-Class, disruptive treatment for multiple conditions. Our applications fall into three major categories: Oncology (chemo/radiation, immuno); Neuro-cardiovascular (stroke, cerebral hypoxia, traumatic brain injury, heart attack); and Respiratory (ARDS). We have positive Phase Ib/IIa human data in glioblastoma (GBM) and stroke, and outstanding pre-clinical results in immune-oncology, heart attack, traumatic brain injury, etc. FDA allowed Phase IIb trials in GBM (Orphan Drug Designation) and stroke, and Canada allowed Phase II trial in ARDS/Covid-19 patients. GBM is the entry point to other oncology indications. Together, our indications address vast market, and potentially will reach an ultimate revenue of $20bn+.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):